NEW YORK (GenomeWeb News) – Molecular Detection today said that it has raised $3.3 million through a Series C financing, which it will use to support the launch of its rapid, molecular Staphylococcus aureus test.

In addition to the financing, Molecular Detection said that it has named Todd Wallach to serve as CEO of the firm. Wallach previously was CFO of Aton Pharma and was a VP of finance at Acquity Pharmaceuticals, before that firm was acquired by Opko Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.